Hancock B W, Bruce L, Sokol R J, Clark A
University Department of Medicine, Royal Hallamshire Hospital, Sheffield, U.K.
Eur J Cancer Clin Oncol. 1988 May;24(5):929-33. doi: 10.1016/0277-5379(88)90204-0.
Transfer factor (TF) was prepared from buffy coats obtained from 493 units of blood taken from healthy donors, including individuals convalescent from various viral infections. It was administered to 22 of 47 patients with Hodgkin's disease undergoing treatment and consenting to take part in this randomized study to determine if TF would enhance their immunity and/or reduce the incidence of subsequent infections. Skin test reactivity was markedly enhanced in those patients receiving TF as opposed to placebo but other immunological assessments showed no significant differences between the groups. TF was not shown to be of benefit in the prevention of infections (including varicella/zoster).
转移因子(TF)是从493单位健康献血者的血沉棕黄层制备而来,这些献血者包括从各种病毒感染中康复的个体。47例接受治疗且同意参与这项随机研究的霍奇金病患者中有22例接受了转移因子治疗,以确定转移因子是否会增强他们的免疫力和/或降低后续感染的发生率。与接受安慰剂的患者相比,接受转移因子的患者皮肤试验反应性明显增强,但其他免疫学评估显示两组之间无显著差异。转移因子在预防感染(包括水痘/带状疱疹)方面未显示出益处。